Senseonics Reports Q4 Revenue Growth and Future Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 03 2026
0mins
Should l Buy SENS?
Source: NASDAQ.COM
- Significant Revenue Growth: Senseonics reported total revenue of $35.3 million for 2025, a 57% increase from $22.5 million in 2024, indicating strong demand and market share growth in the continuous monitoring systems sector.
- Widened Loss Explanation: The fourth-quarter loss widened to $20.8 million, primarily due to increased costs associated with the commercialization of Eversense, although the loss per share remained at $0.46, reflecting the cost pressures faced during market expansion.
- Optimistic Future Outlook: The company expects global net revenue for 2026 to reach approximately $58-$62 million, representing a year-over-year growth of 65% to 76%, driven by the transition of Eversense commercialization back in-house, enhancing sales and marketing infrastructure.
- Product Innovation and Market Expansion: Eversense 365 received FDA approval and launched in the U.S. in October 2024, with plans to expand into Germany, Italy, Spain, and Sweden, further solidifying its leadership position in the global market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SENS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SENS
Wall Street analysts forecast SENS stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 6.310
Low
9.00
Averages
18.70
High
31.00
Current: 6.310
Low
9.00
Averages
18.70
High
31.00
About SENS
Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems Eversense 365 and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. Its CGM systems are indicated for continually measuring glucose levels for up to 365 days for Eversense 365 and 180 days for Eversense E3 in persons with diabetes age 18 and older. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Senseonics Reports Q4 Revenue Growth and Future Outlook
- Significant Revenue Growth: Senseonics reported total revenue of $35.3 million for 2025, a 57% increase from $22.5 million in 2024, indicating strong demand and market share growth in the continuous monitoring systems sector.
- Widened Loss Explanation: The fourth-quarter loss widened to $20.8 million, primarily due to increased costs associated with the commercialization of Eversense, although the loss per share remained at $0.46, reflecting the cost pressures faced during market expansion.
- Optimistic Future Outlook: The company expects global net revenue for 2026 to reach approximately $58-$62 million, representing a year-over-year growth of 65% to 76%, driven by the transition of Eversense commercialization back in-house, enhancing sales and marketing infrastructure.
- Product Innovation and Market Expansion: Eversense 365 received FDA approval and launched in the U.S. in October 2024, with plans to expand into Germany, Italy, Spain, and Sweden, further solidifying its leadership position in the global market.
See More
Senseonics Reports Transformative Q4 2025 Earnings with Strong Growth
- Significant Revenue Growth: In Q4 2025, Senseonics reported net revenue of $14.3 million, a 72% increase year-over-year, with $12.1 million coming from the U.S. market, indicating strong demand and market penetration in diabetes management.
- Successful Strategic Transition: The company has successfully transitioned to a fully integrated developer, manufacturer, and seller, eliminating revenue sharing with Ascensia by bringing sales and customer service in-house, which enhances responsiveness to customer needs, with projected global net revenue of $58 million to $62 million for 2026.
- Market Expansion Plans: Senseonics plans to increase direct-to-consumer marketing spending to $12 million to $15 million in 2026, aiming to double its patient base again, reflecting a proactive response to market demand and growth opportunities.
- Optimistic Financial Outlook: Despite a net loss of $69.1 million in 2025, the company expects gross profit margins to exceed 50% in 2026, with most revenue anticipated in the second half of the year, demonstrating confidence in future growth and effective strategic positioning.
See More
Senseonics Reports 72.3% Revenue Growth in Q4
- Significant Revenue Growth: Senseonics reported Q4 2025 revenue of $14.3 million, marking a 72.3% year-over-year increase and exceeding expectations by $0.1 million, indicating strong performance and demand in the CGM market.
- Gross Profit Surge: The gross profit for Q4 reached $7.7 million, a substantial increase from $4.0 million in Q4 2024, primarily due to reduced one-time charges from the transition from Eversense E3 to Eversense 365, enhancing the company's profitability.
- R&D Expense Reduction: Q4 2025 R&D expenses decreased by $0.6 million year-over-year to $8.8 million, mainly due to the completion of Eversense 365 clinical trials and headcount reductions, providing greater flexibility for future resource allocation.
- Widening Net Loss: Despite revenue and gross profit growth, the net loss for Q4 expanded to $20.8 million, or $0.46 per share, compared to a net loss of $15.5 million in Q4 2024, reflecting increased pressure from significantly higher selling, general, and administrative expenses.
See More
Senseonics Scheduled to Announce Q4 Earnings on March 2
- Earnings Announcement Schedule: Senseonics is set to announce its Q4 earnings on March 2 after market close, with consensus EPS estimate at -$0.43 and revenue expected to reach $14.2 million, reflecting a significant 71.1% year-over-year growth, which could have a substantial impact on the company's market performance.
- Performance Expectation Analysis: Over the past year, Senseonics has beaten EPS estimates 25% of the time and revenue estimates 75% of the time, indicating a relative stability in managing market expectations, which may enhance investor confidence.
- Estimate Revision Dynamics: In the last three months, both EPS and revenue estimates for Senseonics have seen one upward revision with no downward adjustments, suggesting analysts' optimistic outlook on the company's future performance, potentially attracting more investor interest.
- Industry Impact: Senseonics' Eversense 365 is considered a game changer in the continuous glucose monitoring industry, and if the earnings report meets expectations, it will further solidify its market leadership position and drive long-term growth for the company.
See More
Strong Performance of European High Growth Tech Companies, Genmab Reports $3.85 Billion Revenue
- Market Resilience: The pan-European STOXX Europe 600 Index rose by 0.77%, supported by strong economic data and earnings results, indicating a cautious optimism in the market despite mixed performances among major stock indexes.
- Genmab's Innovative Partnership: Genmab's strategic alliance with Anthropic aims to integrate AI into its R&D processes, enhancing the efficiency of its antibody product clinical developments, which is expected to solidify its leading position in oncology.
- LINK Mobility's Recovery Potential: Despite a 40.4% contraction in earnings growth, LINK Mobility Group Holding is projected to achieve an annual earnings growth of 71.1%, significantly surpassing the Norwegian market's expectation of 15%, highlighting its strong recovery potential.
- Sensirion's Technological Leadership: Sensirion Holding AG excels in sensor technology with a 5.9% annual revenue growth and a forecasted 25.8% earnings growth, with innovations in environmental monitoring technology further enhancing its market competitiveness.
See More
Senseonics (SENS) Reports Q4 2025 Revenue of ~$14.2M with 103% New Patient Growth
- Significant Revenue Growth: Senseonics reported preliminary unaudited Q4 2025 revenue of approximately $14.2 million and annual revenue of about $35.2 million, indicating strong market performance, with expectations for 2026 global net revenue to reach $58-$62 million, reflecting a growth of 65% to 76%.
- Innovative Patient Growth: The company achieved a remarkable 103% new patient growth in the U.S. during Q4, marking the largest addition of new patients in its history, primarily driven by effective direct-to-consumer marketing strategies, showcasing the effectiveness of its promotional efforts and enhanced brand influence.
- Gross Margin Expectations: Senseonics anticipates a gross margin of approximately 50% for 2026, which will further enhance its profitability and provide funding support for future investments and expansions, reflecting success in cost control and product pricing strategies.
- Enhanced Financial Transparency: The company plans to release its Q4 and full-year 2025 financial results on March 2, 2026, which will provide more financial details and bolster investor confidence in the company's future development, while also expecting a cash and cash equivalents balance of about $94.3 million as of December 31, 2025.
See More
Senseonics Reports Q4 Revenue Growth and Future Outlook
- Significant Revenue Growth: Senseonics reported total revenue of $35.3 million for 2025, a 57% increase from $22.5 million in 2024, indicating strong demand and market share growth in the continuous monitoring systems sector.
- Widened Loss Explanation: The fourth-quarter loss widened to $20.8 million, primarily due to increased costs associated with the commercialization of Eversense, although the loss per share remained at $0.46, reflecting the cost pressures faced during market expansion.
- Optimistic Future Outlook: The company expects global net revenue for 2026 to reach approximately $58-$62 million, representing a year-over-year growth of 65% to 76%, driven by the transition of Eversense commercialization back in-house, enhancing sales and marketing infrastructure.
- Product Innovation and Market Expansion: Eversense 365 received FDA approval and launched in the U.S. in October 2024, with plans to expand into Germany, Italy, Spain, and Sweden, further solidifying its leadership position in the global market.
See More
Senseonics Reports Transformative Q4 2025 Earnings with Strong Growth
- Significant Revenue Growth: In Q4 2025, Senseonics reported net revenue of $14.3 million, a 72% increase year-over-year, with $12.1 million coming from the U.S. market, indicating strong demand and market penetration in diabetes management.
- Successful Strategic Transition: The company has successfully transitioned to a fully integrated developer, manufacturer, and seller, eliminating revenue sharing with Ascensia by bringing sales and customer service in-house, which enhances responsiveness to customer needs, with projected global net revenue of $58 million to $62 million for 2026.
- Market Expansion Plans: Senseonics plans to increase direct-to-consumer marketing spending to $12 million to $15 million in 2026, aiming to double its patient base again, reflecting a proactive response to market demand and growth opportunities.
- Optimistic Financial Outlook: Despite a net loss of $69.1 million in 2025, the company expects gross profit margins to exceed 50% in 2026, with most revenue anticipated in the second half of the year, demonstrating confidence in future growth and effective strategic positioning.
See More
Senseonics Reports 72.3% Revenue Growth in Q4
- Significant Revenue Growth: Senseonics reported Q4 2025 revenue of $14.3 million, marking a 72.3% year-over-year increase and exceeding expectations by $0.1 million, indicating strong performance and demand in the CGM market.
- Gross Profit Surge: The gross profit for Q4 reached $7.7 million, a substantial increase from $4.0 million in Q4 2024, primarily due to reduced one-time charges from the transition from Eversense E3 to Eversense 365, enhancing the company's profitability.
- R&D Expense Reduction: Q4 2025 R&D expenses decreased by $0.6 million year-over-year to $8.8 million, mainly due to the completion of Eversense 365 clinical trials and headcount reductions, providing greater flexibility for future resource allocation.
- Widening Net Loss: Despite revenue and gross profit growth, the net loss for Q4 expanded to $20.8 million, or $0.46 per share, compared to a net loss of $15.5 million in Q4 2024, reflecting increased pressure from significantly higher selling, general, and administrative expenses.
See More
Senseonics Scheduled to Announce Q4 Earnings on March 2
- Earnings Announcement Schedule: Senseonics is set to announce its Q4 earnings on March 2 after market close, with consensus EPS estimate at -$0.43 and revenue expected to reach $14.2 million, reflecting a significant 71.1% year-over-year growth, which could have a substantial impact on the company's market performance.
- Performance Expectation Analysis: Over the past year, Senseonics has beaten EPS estimates 25% of the time and revenue estimates 75% of the time, indicating a relative stability in managing market expectations, which may enhance investor confidence.
- Estimate Revision Dynamics: In the last three months, both EPS and revenue estimates for Senseonics have seen one upward revision with no downward adjustments, suggesting analysts' optimistic outlook on the company's future performance, potentially attracting more investor interest.
- Industry Impact: Senseonics' Eversense 365 is considered a game changer in the continuous glucose monitoring industry, and if the earnings report meets expectations, it will further solidify its market leadership position and drive long-term growth for the company.
See More
Strong Performance of European High Growth Tech Companies, Genmab Reports $3.85 Billion Revenue
- Market Resilience: The pan-European STOXX Europe 600 Index rose by 0.77%, supported by strong economic data and earnings results, indicating a cautious optimism in the market despite mixed performances among major stock indexes.
- Genmab's Innovative Partnership: Genmab's strategic alliance with Anthropic aims to integrate AI into its R&D processes, enhancing the efficiency of its antibody product clinical developments, which is expected to solidify its leading position in oncology.
- LINK Mobility's Recovery Potential: Despite a 40.4% contraction in earnings growth, LINK Mobility Group Holding is projected to achieve an annual earnings growth of 71.1%, significantly surpassing the Norwegian market's expectation of 15%, highlighting its strong recovery potential.
- Sensirion's Technological Leadership: Sensirion Holding AG excels in sensor technology with a 5.9% annual revenue growth and a forecasted 25.8% earnings growth, with innovations in environmental monitoring technology further enhancing its market competitiveness.
See More
Senseonics (SENS) Reports Q4 2025 Revenue of ~$14.2M with 103% New Patient Growth
- Significant Revenue Growth: Senseonics reported preliminary unaudited Q4 2025 revenue of approximately $14.2 million and annual revenue of about $35.2 million, indicating strong market performance, with expectations for 2026 global net revenue to reach $58-$62 million, reflecting a growth of 65% to 76%.
- Innovative Patient Growth: The company achieved a remarkable 103% new patient growth in the U.S. during Q4, marking the largest addition of new patients in its history, primarily driven by effective direct-to-consumer marketing strategies, showcasing the effectiveness of its promotional efforts and enhanced brand influence.
- Gross Margin Expectations: Senseonics anticipates a gross margin of approximately 50% for 2026, which will further enhance its profitability and provide funding support for future investments and expansions, reflecting success in cost control and product pricing strategies.
- Enhanced Financial Transparency: The company plans to release its Q4 and full-year 2025 financial results on March 2, 2026, which will provide more financial details and bolster investor confidence in the company's future development, while also expecting a cash and cash equivalents balance of about $94.3 million as of December 31, 2025.
See More
